Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy

Summary

The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.

Timeline

Start

2013-01

Primary completion

2013-04

Completion

2013-09

Publications

• Results Croquette M, Faugeroux A, Fonlupt C, Godet J, Frouin E, Garcia M, Bernard FX, Cordier-Dirikoc S, Pedretti N, Larid G, Favot L, Roblot P, Boutin D, Hainaut-Wierzbicka E, Heymann D, Lecron JC, Morel F, Jegou JF. IL-34 Exerts Anti-Inflammatory Activities on Keratinocytes and Is Downregulated in Psoriatic-Inflamed Skin. J Invest Dermatol. 2023 Dec;143(12):2521-2524.e5. doi: 10.1016/j.jid.2023.05.023. Epub 2023 Jun 12. No abstract available.
• Results Buffiere-Morgado A, Couderc E, Delwail A, Favot L, Jegou JF, Solau E, Guillet G, Lecron JC, Morel F. Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy. Eur J Dermatol. 2017 Dec 1;27(6):579-589. doi: 10.1684/ejd.2017.3127.

Drugs

Indications